Corn silk extract improves benign prostatic hyperplasia in experimental rat model

Abstract

BACKGROUND/OBJECTIVESThis study was conducted to investigate the effect of a corn silk extract on improving benign prostatic hyperplasia (BPH).MATERIALS/METHODSThe experimental animals, 6-week-old male Wistar rats, were divided into sham-operated control (Sham) and experimental groups. The experimental group, which underwent orchiectomy and received subcutaneous injection of 10 mg/kg of testosterone propionate to induce BPH, was divided into a Testo Only group that received only testosterone, a Testo+Fina group that received testosterone and 5 mg/kg finasteride, a Testo+CSE10 group that received testosterone and 10 mg/kg of corn silk extract, and a Testo+CSE100 group that received testosterone and 100 mg/kg of corn silk extract. Prostate weight and concentrations of dihydrotestosterone (DHT), 5α-reductase 2 (5α-R2), and prostate specific antigen (PSA) in serum or prostate tissue were determined. The mRNA expressions of 5α-R2 and proliferating cell nuclear antigen (PCNA) in prostate tissue were also measured.RESULTSCompared to the Sham group, prostate weight was significantly higher in the Testo Only group and decreased significantly in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups (P < 0.05), results that were consistent with those for serum DHT concentrations. The concentrations of 5α-R2 in serum and prostate as well as the mRNA expression of 5α-R2 in prostate were significantly lower in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups than that in the Testo Only group (P < 0.05). Similarly, the concentrations of PSA in serum and prostate were significantly lower in the Testo+Fina, Testo+CSE10, and Testo+CSE100 groups (P < 0.05) than in the Testo Only group. The mRNA expression of PCNA in prostate dose-independently decreased in the Testo+CSE-treated groups (P < 0.05).CONCLUSIONSBPH was induced through injection of testosterone, and corn silk extract treatment improved BPH symptoms by inhibiting the mRNA expression of 5α-R2 and decreasing the amount of 5α-R2, DHT, and PSA in serum and prostate tissue.

Role of PPAR‐α agonist fenofibrate in the treatment of induced benign prostatic hyperplasia with dysplastic changes in rats

“…Elevated PSA level is found in BPH and cancer prostate and this could be detected in our model of BPH with dysplastic changes, which showed marked elevation of PSA in group III. These results can be supported by previous studies [18].…”

“…Moreover, cleaved caspase3 immunoexpression significantly decreased in group III but highly overexpressed in group IV group. These findings are supported by different studies .…”

A histological study of the effect of panax ginseng versus finasteride on induced benign prostatic hyperplasia in rats with potentiality of spontaneous recovery

“…As androgen was known as a key risk factor implicated in the pathogenesis of BPH. Added to that it was a prevalent method causing hyperplasia mainly in the ventral lobe of prostate [12,24] . The prostatic ventral lobe is the most commonly studied as it behaves like that of human prostate and it is the most androgen dependent lobe of prostate [25] .…”

Corn silk decoction for blood lipid in patients with angina pectoris: A systematic review and meta‐analysis

“…Then, we screened the titles and abstracts of studies for potential trials and only remained 16 studies after removing obviously unrelated studies. Next, we removed the reviews (Hasanudin, Hashim, & Mustafa, 2012) and basic experimental researches (Bai, Hai, Xi, Liang, & Liu, 2010;Cha et al, 2016;Chaiittianan, Sutthanut, & Rattanathongkom, 2017;Farsi et al, 2008;Guo et al, 2017;Ho, Li, Lo, Chen, & Hsiang, 2017;Kim et al, 2017;Lee et al, 2017). We also removed RCTs without AP patients (George & Idu, 2015;Yang, 2011) or not reporting the blood lipid level (M. Chen, 2014).…”